Tirzepatide Half Life

What is the half life of tirzepatide?

Tirzepatide has an elimination half-life of about 5 days, according to the tirzepatide prescribing information (FDA).

Half-life is the time it takes for the amount of a compound in the blood to fall by half. A 5-day figure is long for an injectable peptide. Tirzepatide binds extensively to plasma albumin, a protein that circulates in blood, which slows its clearance and stretches the half-life (tirzepatide prescribing information, FDA).

Because the half-life is measured across a study population, the real value for any single person shifts with body weight, kidney and liver function, and other factors. The 5-day number is the average that clinical dosing is built around, not a fixed value.

Why does a 5-day half life mean once-weekly dosing?

A half-life of about 5 days means a meaningful fraction of each dose is still in circulation seven days later, so weekly injection keeps drug levels inside a working range without daily dosing.

After one half-life (about 5 days), roughly half of a dose remains. By day 7, when the next dose is due, levels have not fallen to zero, so each weekly dose adds to what is left rather than starting from empty. That overlap is why the pivotal trials used a once-weekly schedule: SURMOUNT-1 dosed tirzepatide once weekly (Jastreboff et al., 2022), and SURPASS-2 compared once-weekly tirzepatide against once-weekly semaglutide (Frias et al., 2021).

How long until tirzepatide reaches steady state?

Steady state is reached after about 4 weeks of once-weekly dosing, per the tirzepatide prescribing information (FDA).

A general pharmacology rule is that a compound reaches steady state, the point where the amount going in balances the amount clearing out, after about 4 to 5 half-lives. For a 5-day half-life that works out to roughly 20 to 25 days, or about 4 weeks. This is one reason trial protocols start low and raise the dose in steps over the first weeks rather than beginning at a maintenance level.

What dose ranges did tirzepatide trials report?

SURMOUNT-1 reported once-weekly maintenance doses of 5, 10, and 15 mg reached through gradual escalation (Jastreboff et al., 2022); these are research-reported figures, not a recommendation, and a personal dose is a clinician decision.

Note the escalation pattern. Because steady state takes about 4 weeks and side effects such as nausea tend to track with rising levels, the trials raised the dose slowly. None of these figures is guidance for an individual; they describe what participants received under medical supervision.

How does tirzepatide half life compare to semaglutide?

Both are long-acting and dosed once weekly; tirzepatide's half-life is about 5 days, and semaglutide is given on the same weekly rhythm.

Both compounds were tested on weekly schedules, and their long durations in the body support that spacing. In a head-to-head trial, once-weekly tirzepatide produced greater weight and glucose reductions than once-weekly semaglutide (Frias et al., 2021). Half-life alone does not decide outcomes; it sets the dosing rhythm rather than the size of the effect.

Does stopping tirzepatide clear it quickly?

No; with a 5-day half-life, tirzepatide takes roughly 4 to 5 weeks to clear almost completely after the last dose, and trials show weight tends to return as levels fall.

The same rule of about 4 to 5 half-lives that governs steady state also governs washout. Roughly 4 to 5 weeks after a final dose, blood levels are near zero. As the drug effect fades, appetite signaling drifts back toward its prior baseline. In SURMOUNT-4, participants who stopped tirzepatide regained a large share of the weight they had lost (Aronne et al., 2024), and a similar pattern followed semaglutide withdrawal in the STEP 1 extension (Wilding et al., 2022). Part of this reflects adaptive thermogenesis, the body's tendency to defend a higher weight after loss (Rosenbaum and Leibel, 2010). This is loss of drug effect over time, not a defect in the compound.